This dataset covers 4,741 published records filed between 2015 and the 2026 data cut-off, spanning platelet-rich plasma, bone marrow aspirate and related biologic augmentation approaches together with their preparation protocols, leukocyte-content controls and dosing regimens. The true current total is somewhat higher than shown, because publication typically lags filing by around eighteen months, so the most recent one to two years are still filling in. Treat 4,741 as the count of records published and indexed as of the cut-off, not a final tally for those most recent years.

The ranking covers 100 assignees, with the leader holding 324 records against 164 at fifth place and 113 at tenth — a clear gap between the top holder and the rest of the field. The top five combined account for 28.1% of all 4,741 records in scope, and the top ten reach 42.6%. Below that the ranking thins into a long tail of assignees with only a handful of filings each, which is typical of a field where large biopharma portfolios intersect with a broader base of smaller or single-invention filers.

Filings rose to a peak of 400 records in 2019 and have eased since; the clearest complete comparison is 2021’s 351 records falling to 190 in 2024, a -46% change over that three-year span. Because publication lags filing by roughly eighteen months, 2025 and 2026 figures in the raw trend are understated and should not be read as evidence of a continuing decline. The honest read is a real pullback from the 2019 peak through 2024, with the more recent picture still incomplete.